疫苗公司中慧生物-B(2627.HK)明日截飞，截止目前，券商至少为其借出930.52亿港元孖展，以公开发售集资额5184万港元计，相当于公开发售超购逾1793倍。 中慧生物计划集资最多5.18亿港元，本周五(8日)挂牌，中信证券及招银国际为保荐人。中慧生物有两款核心产品，包括四价流感病毒亚单位疫苗和在研冻干人用狂犬病疫苗。公司今年首季的亏损按年扩大至8730万元人民币。
疫苗公司中慧生物-B(2627.HK)明日截飞，截止目前，券商至少为其借出930.52亿港元孖展，以公开发售集资额5184万港元计，相当于公开发售超购逾1793倍。 中慧生物计划集资最多5.18亿港元，本周五(8日)挂牌，中信证券及招银国际为保荐人。中慧生物有两款核心产品，包括四价流感病毒亚单位疫苗和在研冻干人用狂犬病疫苗。公司今年首季的亏损按年扩大至8730万元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.